| Outcome Measures: |
Primary: Patient Overall Preference, The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d "Overall, what is your level of preference for each of the insulin delivery systems?" 5 points scale: from 1=Not preferred to 5= Always preferred, At week 4 (end of crossover phase) | Secondary: Patient Preference Composite Score, The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire: * Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar? * Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin? * Question 14c: How strongly would you prefer each insulin delivery system for long-term use? Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15., At week 4 (end of crossover phase)|Healthcare Professional's (HCP) Recommendation, The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: "Overall, how strongly would you recommend each of the insulin delivery systems for your patients?" 5 points scale: from 1= Not Recommended to 5= Recommended, At week 4 (end of crossover phase)|Change in Fasting Plasma Glucose (FPG), From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)|Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL, At week 10 (end of re-randomization phase)|Change in Lantus Dose Injected Per Day, From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)|Percentage of Patients Achieving HbA1c Goal, Percentage of patients achieving HbA1c \< 7% at Week 40 (end of the observational phase), measured at week 40 or at study discontinuation|Time to First Observation of HbA1c <7%, From week 10 to week 40 (observational phase)|Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase, From baseline to week 4 (crossover phase)|Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase, From week 4 to week 10 (re-randomization phase)|Percentage of Patients Who Discontinued Investigational Product During the Observational Phase, From week 10 to week 40 (observational phase) | Other: Number of Patients With Hypoglycemic Events, The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) \<70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG \<36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG \>70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs)., each study phase (crossover, re-randomization, observational) up to 40 weeks
|
